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Abstract: Niemann-Pick Disease, type C1 (NPC1) is a rapidly progressive neurodegenerative disorder
characterized by cholesterol sequestration within late endosomes and lysosomes, for which no reliable
imaging marker exists for prognostication and management. Cerebellar volume deficits are found
to correlate with disease severity and diffusion tensor imaging (DTI) of the corpus callosum and
brainstem, which has shown that microstructural disorganization is associated with NPC1 severity.
This study investigates the utility of cerebellar DTI in clinical severity assessment. We hypothesize
that cerebellar volume, fractional anisotropy (FA) and mean diffusivity (MD) negatively correlate
with NIH NPC neurological severity score (NNSS) and motor severity subscores. Magnetic resonance
imaging (MRI) was obtained for thirty-nine NPC1 subjects, ages 1–21.9 years (mean = 11.1, SD = 6.1).
Using an atlas-based automated approach, the cerebellum of each patient was measured for FA, MD
and volume. Additionally, each patient was given an NNSS. Decreased cerebellar FA and volume,
and elevated MD correlate with higher NNSS. The cognition subscore and motor subscores for eye
movement, ambulation, speech, swallowing, and fine motor skills were also statistically significant.
Microstructural disorganization negatively correlated with motor severity in subjects. Additionally,
Miglustat therapy correlated with lower severity scores across ranges of FA, MD and volume in all
regions except the inferior peduncle, where a paradoxical effect was observed at high FA values.
These findings suggest that DTI is a promising prognostication tool.
Keywords: Niemann-Pick; NPC; diffusion tensor imaging; DTI; cerebellum; motor function
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1. Introduction
Niemann-Pick disease type C (NPC) is an autosomal recessive lysosomal storage disorder,
characterized by a mutation in NPC1 or NPC2, resulting in an accumulation of intracellular
unesterifified cholesterol and lipids [1]. The estimated prevalence of NPC is 1 in 100,000 European
births, with Niemann-Pick disease type C1 (NPC1) accounting for 95% of cases, and Niemann-Pick
disease type C2 (NPC2), 5% [2,3]. NPC1 arises from a mutation in NPC1, which encodes for a
transmembrane protein incorporated into late endosomes [4]. When NPC1 is dysfunctional, lipids
accumulate in the endosomal system of the cell, which precipitates a cascade of cellular events, leading
to neuronal death. The clinical progression of NPC often begins with prolonged neonatal jaundice,
followed by relatively normal early childhood development before the observable onset of ataxia,
dysarthria, dementia, seizures, dystonia and neurocognitive deficits. These signs are commonly
accompanied by hepatosplenomegaly and can occur at any age, but are most commonly present in
children [5].
In early onset NPC, disease progression is rapid, and expanding our arsenal of severity markers
is essential to improving care. Increased serum levels of galectin-3 (LGALS3), a pro-inflammatory
molecule, and cathepsin D (CTSD), a lysosomal aspartic protease, as well as various cholesterol
oxidation products have been found to be potential serum biomarkers in murine models that may
aid in diagnosis and therapeutic monitoring in NPC1 patients [6,7]. Imaging markers are yet to be
developed. Lee et al. (2014) found decreased volume and microstructural organization of the corpus
callosum were associated with increased NIH NPC severity scores (NNSS) [8]. Cerebellar volume and
fractional anisotropy (FA) have been shown to be significantly decreased in adult NPC patients [9,10].
However, there have been no publications to date documenting the in vivo cerebellar microstructural
abnormalities and their clinical consequences in NPC patients using DTI [11,12]. This is the first study
that aims to examine the relationship between cerebellar DTI measures and NPC1 disease severity
in a pediatric population. A secondary analysis then examined the effects of miglustat status on
these DTI measures. The DTI measures in this study include FA, a measure of diffusion directionality,
and mean diffusivity (MD), and a measure of diffusion magnitude. Both are measures of brain
microstructural abnormality that are not identified by routine MRI scans. Lower FA and higher MD
represent microstructural disorganization in the region examined and are associated with impaired
neuronal conduction. We hypothesize that decreased FA and increased MD is associated with increased
NNSS and particularly, increased motor severity subscores.
2. Materials and Methods
2.1. Study Sample
The Eunice Kennedy Shriver National Institute of Child Health and Human Development,
Institutional Review Board (Bethesda, MD, USA) reviewed and approved this study. Parents or
legal guardians voluntarily enrolled their children, provided written informed consent, and assent
was obtained when possible. Thirty-nine pediatric subjects diagnosed with NPC1 following clinical
examination and biochemical or genetic testing comprised this study’s sample.
2.2. Image Acquisition and Analysis
Between August 2006 and January 2012, one MRI scan was performed on each patient, each
sedated with propofol for the duration of the scan. A Philips Achieva 3.0T magnetic resonance scanner
(Philips, Amsterdam, Netherlands) was used to obtain axial magnetization-prepared rapid-gradient
echo (MPRAGE), T2-weighted imaging (T2WI), and DTI sequences, without gaps. Acquisition
parameters used for T2WI and DTI can be found in Table 1. Diffusion weighting was performed along
16 axes with a b value of 800 s/mm2. The automated atlas-based segmentation of the cerebellum was
based on the T2-weighted images, which uses a reference map in place of explicit anatomic landmarks
to generate sections.
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Table 1. Acquisition Parameters for T2WI and DTI.
Acquisition Parameter T2WI DTI
Repetition Time (TR) 5400 ms 6401 ms
Echo Time (TE) 100 ms 60 ms
Field of View (FOV) 220 × 165 mm 224 × 224 mm
Acquisition Matrix 384 × 227 112 × 112
Reconstruction Matrix 512 × 512 128 × 128
In-Plane Resolution 0.43 × 0.43 mm/pixel 1.75 × 1.75 mm/pixel
Acquisition Duration 2:25 2:27
Slice Thickness 5 mm 2 mm
Number of Axial Slices 28 70
A scanner upgrade occurred in 2010, and the resulting changes in MPRGE scan parameters can
be found in Table 2.
Table 2. Changes in Patient MPRGE Parameters with Scanner Upgrade (2010).
Scan Parameters Axial MPRGE < 2010 Axial MPRGE > 2010 (Upgrade)
Repetition Time (TR) 8.2 ms 11.4 ms
Echo Time (TE) 3.8 ms 6.5 ms
FA 8◦ 6◦
Field of View (FOV) 256 mm 220 mm
Acquisition Matrix 256 × 256 256 × 131
Reconstruction Matrix 256 × 256 256 × 256
Slice Thickness 1.0 mm 1.0 mm
Number of Excitations 1 2
Hardware and software updates that occurred while the scans were performed did not affect
fractional anisotropy values, as the same b value was used throughout. Volume measurements
were obtained by counting the number of voxels in the original image that mapped into the
atlas-defined segment.
As the shortest TE is desired when using DTI, we minimized the image matrix and used a relatively
small b value in our study to shorten TE as much as possible. The shortest TE, without compromising
diffusion weighting, is desired, so a compromise was achieved between enough diffusion weighting
and signal to noise ratio (SNR). Additionally, the use of a Philips scanner, which uses the single
spin-echo sequence rather than the dual spin-echo sequence, which is an option used by Siemens
and GE scanners, further contributed to a shorter TE. With a shorter TE, the signal:noise ratio is
expected to be higher due to T2-relaxation decay. DTI is designed to achieve the shortest TE possible,
as determined by gradient strength, gradient hardware performance, used pulse sequence, image
matrix size, bandwidth, the skew rate, and parallel imaging factor. A comprehensive analysis of the
signal:noise ratio and bias using similar imaging protocol has been published [13].
All DTI data sets were processed offline using DTIStudio software. Using a 12-mode affine
transformation of automated image registration, the raw diffusion-weighted images were coregistered
to a b = 0 image [14]. The six independent elements of the diffusion tensor (Dxx, Dyy, Dzz, Dxy,
Dxz, Dyz), including FA and MD were then calculated. The FA and MD values were determined
as an average of the region of interest (e.g. cerebellum). Large deformation diffeomorphic metric
mapping (LDDMM) was performed to correct distortion caused by b0 susceptibility in accordance with
a previous publication [15], using T2WI as the target and the b = 0 image as the DTI data. After skull
stripping, the images were normalized to the JHU-DTI MNI “Eve” template with a nine-parameter
affine transformation of automated image registration by using b0 images after distortion correction.
A nonlinear transformation, accomplished by dual-contrast LDDMM, was applied [16,17] using FA
and Trace images as two channel inputs. The nonlinear image transformation and the atlas-based
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parcellation were performed using DiffeoMap and RoiEditor [14,18–20]. Because these procedures
are reciprocal, the inverse-transformed brain parcellation map was superimposed onto the original
diffusion tensor images and led to parcellation of the brain into 130 anatomic structures [18–20].
After the quantitative values were obtained, the cerebrospinal fluid spaces were excluded by a mean
diffusivity threshold set at 0.0020 mm2/s. Data were excluded based on motion degradation and poor
image quality, as assessed by a neuroradiologist (EB) and neurologist (SY) with specialty in DTI.
A parcellation map was thus created to measure cerebellar FA and volume for each patient.
The map enabled segmentation of the cerebellum and its associated peduncles into ten regions,
defining right and left halves of each structure relative to the midline: left cerebellum, right cerebellum,
left superior cerebellar peduncle, right superior cerebellar peduncle, left middle cerebellar peduncle,
right middle cerebellar peduncle, left inferior cerebellar peduncle, right inferior cerebellar peduncle,
left cerebellar white matter and right cerebellar white matter. FA and volume were determined for
each region.
2.3. Severity Score, DTI and Volume Measurements
A neurological severity scoring system for NPC based on clinical evaluation was developed to aid
monitoring the course of the disease. The system assigns an NNSS to each patient, derived from the
sum of 17 subcategory severity scores (nine major and eight minor domains) in the following areas: eye
movement, ambulation, speech, swallowing, motor, cognition, hearing, memory, seizures, cataplexy,
narcolepsy, behavior, psychology, hyperreflexia, incontinence, respiratory, and auditory brain stem
response. A patient’s score increases with disease severity, with a maximum score of 61 points, and the
score is independent of age at onset of NPC, making it applicable to both children and adolescents [21].
In our study, NNSS, as well as all subscores, age at first symptoms, and duration of symptoms were
analyzed in conjunction with DTI and volume.
2.4. Statistical Analyses
Spearman correlation assessed the associations between cerebellar FA, volume, and MD with
NNSS. Raw DTI data were converted to population-averaged z-scores (standardized variables), which
were calculated using an age-matched normal group as controls:
z = (x−µ)/σ (1)
where µ was the mean of the control group and σ was the standard deviation of the control group.
For the control group, the existing clinical database of pediatric MRIs with no remarkable findings was
used. The clinical history of each patient was carefully evaluated by a neuropediatrician, and patients
with apparent abnormal neurological findings, developmental abnormalities, or preterm birth history
were excluded. Images were acquired using a 3T Siemens scanner. DTI: A single-shot echo planar
imaging (EPI) with parallel acquisition; axial orientation; Imaging matrix, 96 × 96; FOV 240 × 240;
thickness 2.5 mm; TE 84 ms; TR 7700 ms; diffusion-weighting along 21 axes with b = 1000 s/mm2;
repeated twice to enhance the SNR. T2 FSE: whole brain; axial orientation; imaging matrix, 320 × 288;
FOV 189 × 210 mm; thickness 3.5 mm; TE = 104 ms, TR = 4280 ms.
There is limited data on the effects of age and cerebellar development with respect to DTI changes.
Z-scores were applied to correct for variability in age among imaging outcome measures. In addition,
we performed a separate multiple regression analysis on the raw DTI data, and compared the results
of the two statistical methods. For multiple regression analysis; NNSS and subscores (dependent
variable) were each regressed on cerebellar FA, volume and MD and age at scan (independent variables
and covariate).
Analysis of covariance (ANCOVA; general linear modeling (SAS/STAT®, 2011)) assessed the
associations between miglustat therapy and NNSS and subscores, with cerebellar volume, FA, and
MD as respective covariates. Each ANCOVA model tested the assumption (null hypothesis) that the
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relationships of NNSS and subscores with cerebellar volume, FA, or MD were statistically similar for,
or didn’t differ among, those receiving vs. not receiving miglustat therapy.
A Wilcoxon-Mann-Whitney test was also performed to assess for different volume, FA and
MD findings in the cerebellum according to a subject’s miglustat status (on vs. off). Two-sided
p-value < 0.05 was considered to be statistically significant.
3. Results
3.1. Sample Demographics
This study’s sample was comprised of 35 pediatric and four young adult subjects diagnosed with
NPC1 by clinical examination and cellular or genetic testing. There were 20 females and 19 males
ranging in age between 1 and 21.9 years (mean 11.1, SD 6.1) (Table 3). The ethnic distribution was
Caucasian (34, 87%), Hispanic (4, 10%), and Hispanic/American Indian (1, 2.6%). NNSS ranged from
1 to 46 points (mean 16.2, SD 11.5). The age at first neurological symptoms ranged from birth to
13 years (mean 2.7, SD 3.6). The duration of neurological symptoms ranged from 1.1 to 16.5 years at
the time of scan (mean 7, SD 4.1). Common presenting symptoms included splenomegaly, jaundice,
and hepatosplenomegaly. Of the twenty-one subjects, 54% were receiving off-label oral miglustat.
Additional demographic information is provided in Table 3.














1 F 21.2 35 VGSP 9 12.2 −
2 M 7.7 5 Fine Motor Limitation 5 2.7 +
3 F 13.1 33 Clumsy, possible VGSP 2 11.1 +
4 M 5 11 Clumsy, Dysarthria 3 2.0 −
5 M 10 14 Fine Motor Limitation 3 7.0 −
6 M 16.3 18 Dysarthria 3 13.3 −
7 F 11.8 22 Clumsy 1.5 10.3 −
8 F 4 26 Clumsy, VGSP 2 2.0 +
9 M 7.7 7 Abnormal Gait 2 5.7 +
10 M 11.8 18 Fine Motor, Coordination Deficit 6 5.8 +
11 M 5.4 8 Clumsy, Speech Delay 2 3.4 +
12 F 5.2 13 Clumsy 1 4.2 +
13 M 4.7 2 None Reported N/A N/A +
14 M 6.1 7 Clumsy 2 4.1 −
15 F 3.8 3 Clumsy 2 1.7 −
16 F 21.5 35 VGSP 5 16.5 −
17 F 6.7 40 Abnormal gait, fine motor limitation 3 3.7 −
18 F 15.7 1 None Reported N/A N/A +
19 F 6.8 27 Gross motor delay 1.5 5.3 +
20 F 12.6 24 VGSP 5 7.6 −
21 F 16.8 23 Learning difficulty 8 8.8 +
22 M 8.4 46 Clumsy 1.5 6.9 −
23 M 1 1 None Reported N/A N/A +
24 M 1.6 4 None Reported N/A N/A −
25 M 17.2 10 Abnormal Gait 12 5.2 +
26 F 8.1 8 Tremor, fine motor limitation 7 1.1 +
27 M 20.3 14 VGSP, slurred speech 13 7.3 −
28 M 6.6 13 VGSP 3.5 3.1 −
29 M 4 2 None Reported N/A N/A −
30 F 12.7 17 Learning disability 8 4.7 +
31 F 21 18 School problems 5 16.0 −
32 F 15.6 12 Gross motor delay 1.2 14.4 +
33 M 17.2 19 Learning disability 6 11.2 −
34 F 21.9 18 Learning disability 11 10.9 −
35 F 17.3 15 Clumsy 7 10.2 +
36 F 13.3 13 Learning disability 7 6.3 +
37 M 15.2 33 Seizures 6 9.2 +
38 F 11.8 16 VGSP 3 8.7 +
39 M 3.8 2 Gross motor delay 2 1.7 +
F = Female; M = Male; SS = National Institutes of Health, Niemann-Pick disease type C neurological severity
score; VGP = Vertical Gaze Palsy; VGSP = Vertical Gaze Supranuclear Palsy; N/A = No data available:
No neurologic symptom reported. “+”= on Miglustat and “−” = off Miglustat.
Diseases 2016, 4, 29 6 of 15
3.2. Cerebellar Fractional Anisotropy (FA)
The cerebellar FA of the right/left inferior and right/left superior peduncles, right white matter,
and right/left/whole cerebellum were negatively correlated with NNSS (Table 4). Various cerebellar
FA were negatively correlated with subscores for eye movement, ambulation, speech, swallowing,
fine motor skills, cognition, seizures, psychology, respiratory, age at first neurological symptoms and
duration of neurological symptoms (Supplementary Table S1). For example, FA of the right/left inferior
and right superior peduncles, and right/left/whole cerebellum were also negatively correlated with
eye movement subscores (Supplementary Table S1). There were no statistically significant correlations
found between cerebellar FA and hearing, memory, cataplexy, narcolepsy, behavior, hyperreflexia,
incontinence, and auditory brain stem response scores.
Table 4. Spearman Correlations of Cerebellar Measures with NIH NPC Severity Score (NNSS).
Cerebellar Measure
FA Volume MD
r p r p r p
R inferior peduncle −0.38 0.02 −0.35 0.03
L inferior peduncle −0.35 0.03
R superior peduncle −0.35 0.03 −0.46 0.003
L superior peduncle −0.41 0.01 −0.49 0.001
R middle peduncle 0.35 0.03
R white matter −0.33 0.04 0.33 0.04
R cerebellum −0.42 0.01 0.37 0.02
L cerebellum −0.35 0.03 0.35 0.03
Whole cerebellum −0.40 0.01 0.37 0.02
R = Right; L = Left; FA = Fractional Anisotropy; MD = Mean Diffusivity.
Multiple regression models of NNSS with the FA of the right inferior peduncle and right/left
white matter, respectively, along with age at scan (covariate) were statistically significant (Table 5).
Also, in models of eye movement (f = 5.74, p < 0.01, R2 = 0.24), ambulation (f = 5.79, p < 0.01, R2 = 0.24),
and swallowing (f = 10.07, p < 0.001, R2 = 0.36) subscores with the right inferior peduncle and age
at scan (covariate); of ambulation (f = 7.46, p < 0.01, R2 = 0.29), speech (f = 4.27, p < 0.05, R2 = 0.19),
and swallowing (f = 10.57, p < 0.001, R2 = 0.37) subscores with the right white matter and age at
scan covariate; and of ambulation (f = 8.56, p < 0.001, R2 = 0.32), speech (f = 6.35, p < 0.01, R2 = 0.26),
swallowing (f = 10.11, p < 0.001, R2 = 0.36) subscores with the left white matter and age at scan covariate;
were statistically significant. There were also statistically significant within-model associations between
the eye movement (f = 6.26, p < 0.01, R2 = 0.26) subscores with the FA measure of the right white
matter and age at scan covariate (negative parameter estimates) and between fine motor skills (f = 4.67,
p < 0.05, R2 = 0.21) and memory (f = 3.30, p < 0.05, R2 = 0.15) subscores with the FA measure of the left
white matter and age at scan covariate (positive parameter estimates) (Supplementary Table S2).
Wilcoxon-Mann-Whitney test results indicated no statistically significant difference between on
and off miglustat groups in FA. ANCOVA models of NNSS in patients on miglustat, with covariate FA
of the R/L inferior and L superior peduncles, were statistically significant (Table 6).
In addition, ANCOVA of swallowing scores and miglustat therapy, with the covariates FA of
the left inferior peduncle (f = 7.71, p < 0.001, R2 = 0.40) and right middle peduncle (f = 4.67, p < 0.05,
R2 = 0.21) were statistically significant. Groups receiving versus groups not receiving miglustat therapy
were found to have significantly lower swallowing subscores, with the FA of the left superior peduncle
(0.82 vs. 1.87) and left middle peduncle (0.81 vs. 1.86), as respective covariates. The groups receiving
miglustat therapy had significantly lower duration of neurological symptom subscores, with the FA
of the left white matter (5.57 vs. 9.07), as the covariate. The statistically significant independent
effect of miglustat therapy on psychology scores, and of FA for eye movement, ambulation, speech,
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cognition, age at first neurological symptoms, and duration of neurological symptom were also noted
(Supplementary Table S3). There were statistically significant interaction effects between miglustat
therapy with the covariates FA of the right/left (Figure 1) inferior peduncles for NNSS, swallowing,
fine motor, cognition, psychology, and duration of neurological symptom (Supplementary Table S3).
Table 5. Multiple Regression of NNSS on Cerebellar Measures and Age at Scan.
Parameter t-Value p< Model f Model p< R2
FA
R inferior peduncle −78.01 −2.14 0.05
6.01 0.01 0.25Age at scan 1.16 3.47 0.01
R white matter −202.26 −2.48 0.05
6.94 0.01 0.28Age at scan 1.16 3.67 0.001
L white matter −214.00 −2.62 0.05
7.38 0.01 0.29Age at scan 1.16 3.76 0.001
Volume
R inferior peduncle −0.03 −2.48 0.05
6.95 0.01 0.28Age at scan 1.02 3.52 0.01
L inferior peduncle −0.03 −2.32 0.05
6.48 0.01 0.26Age at scan 0.94 3.33 0.01
R superior
peduncle −0.03 −3.12 0.01 9.08 0.001 0.34
Age at scan 0.88 3.38 0.01
L superior peduncle −0.03 −3.07 0.01
8.87 0.001 0.33Age at scan 0.85 3.27 0.01
R middle peduncle −0.01 −2.29 0.05
6.42 0.01 0.26Age at scan 1.07 3.50 0.01
L middle peduncle −0.003 −2.42 0.05
6.78 0.01 0.27Age at scan 1.05 3.54 0.01
R white matter −0.003 −2.66 0.05
7.50 0.01 0.29Age at scan 0.94 3.43 0.01
L white matter −0.003 −3.21 0.01
9.42 0.001 0.34Age at scan 1.01 3.78 0.01
MD
R middle peduncle 16112 2.25 0.05
6.31 0.01 0.26Age at scan 0.93 3.29 0.01
L middle peduncle 16918 2.40 0.05
6.71 0.01 0.27Age at scan 0.95 3.37 0.01
R white matter 12378 2.18 0.05
6.12 0.01 0.25Age at scan 0.89 3.20 0.01
R cerebellum 5248.47 2.10 0.05
5.92 0.01 0.25Age at scan 0.58 2.03 0.05
L cerebellum 5035.14 2.08 0.05
5.86 0.01 0.25Age at scan 0.60 2.12 0.05
Whole cerebellum 5182.60 2.10 0.05
5.92 0.01 0.25Age at scan 0.58 2.07 0.05
R = Right; L = Left; FA = Fractional Anisotropy; MD = Mean Diffusivity.
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Table 6. ANCOVA of NNSS and Subcores, Miglustat and Cerebellar Measures.
Type I NNSS f -value p< Type III NNSS f -value p< Model f value Model p< Model R2
FA
Miglustat 266.74 2.58 0.12 197.29 1.91 0.18 4.63 0.01 0.28
R inferior peduncle 600.57 5.82 0.05 503.01 4.87 0.05
Age at scan 565.80 5.48 0.05
Miglustat 266.74 2.59 0.12 263.45 2.56 0.12 4.66 0.01 0.29
L inferior peduncle 530.46 5.15 0.05 442.57 4.30 0.05
Age at scan 642.40 6.24 0.05
Miglustat 266.74 2.37 0.14 122.76 1.09 0.31 3.24 0.05 0.22
L superior peduncle 700.03 6.21 0.05 724.33 6.42 0.05
Age at scan 130.67 1.16 0.29
Volume
Miglustat 266.74 2.73 0.11 165.04 1.69 0.21 5.57 0.01 0.32
R superior peduncle 1299.66 13.32 0.001 1363.60 13.98 0.00
Age at scan 63.98 0.66 0.43 1
Miglustat 266.74 2.48 0.13 85.78 0.80 0.38 3.97 0.05 0.25
L superior peduncle 1011.34 9.40 0.01 846.23 7.87 0.01
Age at scan 2.12 0.02 0.89
MD
Miglustat 266.74 2.51 0.13 463.12 4.35 0.05 4.14 0.05 0.26
R middle peduncle 719.61 6.76 0.05 1001.38 9.41 0.01
Age at scan 334.83 3.15 0.09
Miglustat 266.74 2.44 0.13 345.29 3.16 0.09 3.73 0.05 0.24
L middle peduncle 715.91 6.55 0.05 920.75 8.43 0.01
Age at scan 238.39 2.18 0.15
Miglustat 266.74 2.33 0.14 238.23 2.09 0.16 3.05 0.05 0.21
R white matter 608.32 5.32 0.05 729.96 6.39 0.05
Age at scan 171.50 1.50 0.23
Miglustat 266.74 2.31 0.14 175.21 1.52 0.23 2.90 0.05 0.20
R cerebellum 711.98 6.17 0.05 718.60 6.23 0.05
Age at scan 26.07 0.23 0.64
R = Right; L = Left; FA = Fractional Anisotropy; MD = Mean Diffusivity.
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3.3. Cerebellar Volume
The cerebellar volume of the right inferior and right/left superior peduncles were negatively
corr lated with NNSS (Table 4). Other ce ebellar volumes wer negatively orrelated with
eye movement, ambulation, speech, swallowing, fine motor skills, cognition, seizures, and
hyperreflexia (Supplementary Table S1). Positive correlations were found between the volume
of the right/left/whole cerebellum with ambulation and auditory brain stem response. There
were no statistically significant correlations found between cerebellar volume and hearing, memory,
cataplexy, narcolepsy, behavior, psychology, hyperreflexia, incontinence, respiratory, and duration of
neurological symptom.
Multiple regression models of NNSS with the volume for the right/left inferi r, right/left
super or and right/left middle peduncles, and right/left white matter and age at scan (covariate)
were statistically significant (Table 5). Statistically significant models of eye movement, ambulation,
swallowing, fine motor skills, and cognition with the volume for the right/left superior peduncles and
right/left white matter and age at scan (covariate) were found (Supplementary Table S2). Cerebellar
volume of the right/left inferior peduncles were statistically significant (minimal) parameters, whereas
age at scan was a statistically significant (>minimal) parameter, related to age at first neurological
symptoms (positive direction) and duration of neurological symptoms (negative direction).
Wilcoxon-Mann-W itn y test results indicated no statistically significa t differences in volume of
various cerebellar regions between those on versus those off miglus at th r py.
ANCOVA models of NNSS and miglustat therapy, with the volume of the right/left peduncles
as the covariate, were statistically significant (Table 6). Groups receiving versus groups not receiving
miglustat therapy were found to have significantly lower swallowing subscores (0.78 vs. 1.95) with the
volume of the right inferior peduncle as covariate (f = 4.02, p < 0.05, R2 = 0.26), as well as significantly
lower behavior subscores (0.09 vs. 0.39), with the covariate volume of the left white matter (f = 4.25,
p < 0.05, R2 = 0.27). Statistically significant interaction effects were noted between miglustat therapy
with the volume of the right (Figure 2)/left inferior and right/left middle peduncles for behavior
subscores, and with the volume of the right/left white matter and right/left/whole cerebellum for
auditory brain response subscores (Supplementary Table S3).
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3.4. Cerebellar Mean Diffusivity (MD)
The cerebellar MD of the right middle peduncle, right white matter, and right/left/whole
cerebellum were positively correlated with NNSS (Table 4). MD of other cerebellar regions were
also positively correlated with eye movement, ambulation, speech, swallowing, fine motor skills,
memory, and auditory brain stem response (Supplementary Table S1). For example, MD of the
right/left mid le peduncles, right/l ft white matter, and right/left/whole cerebellum were positively
correlated with speech.
Multiple regression models of NNSS with the MD of the right/left middle peduncles, right white
matter, and right/left/whole cerebellum, and age at scan covariate were statistically significant
(Table 5). Models of eye movement, ambulation, speech, swallowing, memory, and auditory
brain response, with MD of cerebellar regions were also found to be statistically significant.
Wilcoxon-Mann-Whitney test results indicated no statistic lly significant differences in cerebellar
MD b tween those on versus those off miglustat therapy.
ANCOVA models of NNSS and miglustat therapy, with the covariate MD of the right/left middle
peduncles, right white matter, and right cerebellum were statistically significant (Table 6). Similar
to cerebellar FA and Volume, ANCOVA indicated that groups receiving versus groups not receiving
miglustat therapy differed significantly in their swallowing subscores, with MD of the left inferior
(0.83 vs. 1.86; f = 3.35, p < 0.05, R2 = 0.22) and left superior (0.81 vs. 1.88; f = 3.17, p < 0.05, R2 = 0.21;
Figure 3) peduncles as respectiv model covariat s. Comparably, with the covariates MD of the
right inferior and right/left middle peduncles, right white matter, and right/left/whole cerebellum,
the independent effect of miglustat therapy was statistically significant for swallowing subscores
(Supplementary Table S3). For eye movement, ambulation, and speech; the independent effect of
various cerebellar MD, after accounting for miglustat therapy, were statistically significant.
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4. Discussion
This is the first study that aims to examine the relationship between cerebellar DTI measurements
and NPC1 disease severity. FA and MD are DTI measures of brain microstructural abnormality
that are not identified by routine MRI scans. Lower FA and higher MD represent microstructural
disorganization in the region examined. Therefore, we hypothesized that decreased FA and increased
MD in the cerebellum would be correlated with elevated NIH NPC severity scores, particularly higher
motor severity. In our population of NPC1 subjects, deficient cerebellar FA and elevated MD were
associated with higher total NPC neurological severity scores, and motor subscores for eye movement,
ambulation, speech, swallowing fine motor skills, and cognition. Of the ten cerebellar segments
analyzed, superior cerebellar peduncle volume depletion, bilaterally, most consistently correlated with
higher scores in ambulation, speech, swallow and fine motor skills, as well as cognition and overall SS,
as compared to the other segments.
Our hypothesis that a relationship exists between microstructural disorganization/volume
depletion in the cerebellum and NPC disease severity, particularly with motor impairment, was
supported by these findings. The data suggest the value of DTI and volume in assessing the clinical
markers of NPC1 severity in a pediatric sample. In a previous study looking at the correlation
between disease severity and DTI and volume measures in the corpus callosum, it was found that,
of the seventeen components that make up the NNSS, the ambulation and motor subscores correlate
strongest with disease severity [8]. Another recent study by Walterfang et al. (2013) shows a reduction
in NPC grey and white matter cerebellar volumes measures in ten adult NPC patients, when compared
to controls. The volume findings in this study did not correlate with symptom duration or severity, but
did correlate with saccadic gain and ataxia measures [9]. Our data appears to support these findings in
that we report specific clinical measures within the total severity score, such as ambulation, that are
correlated with lower cerebellar volume in specific regions; however, there is greater variability in our
findings with respect to regions correlating with clinical findings. This may be due to methodological
differences between Walterfang and our study, in both cerebellar parcellation and clinical measures of
the disease.
An important consideration regarding these results is the effect of NPC severity on motion and
the effect of motion on quality of the MRIs obtained. Though the possibility of bias at the level
of registration and segmentation effectiveness exists, with motion degradation as a cause of bias,
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all subjects were MRI scanned under sedation and all motion degraded images were excluded from
the study. Therefore, in principal, motion should not factor in as a confounder with FA and higher
severity score. We will add these comments to the manuscript discussion.
The specific pathophysiologic mechanism underlying our findings is unknown. Studies of murine
models suggest that various pathways play a role, including decreased vitamin E and calcium-binding
proteins that increase susceptibility of purkinje cells to oxidative stress, causing decreased dendritic
branching and cell death, as well as cellular disorganization on a microstructural level [22–25]. In these
murine models, reactive metabolic changes that lead to alterations in synaptic strength and long-term
depression are observed, which are thought to result in progressive purkinje neurotoxicity and
initiation of apoptosis and cell death [22,23,26,27].
Our findings support the idea that DTI is a tool for measuring neurodevelopmental impairment.
The derived FA and volume may be applied to evaluate NPC disease severity. Previous studies support
DTI and volumetric analysis of both grey and white matter as useful modalities for indexing illness
stage and monitoring response to treatment [9,12]. DTI analysis of the corpus callosum showed a
correlation between volume deficits and increased SS and MSS [8]. Future studies investigating the
effects of therapy on NPC may consider using brain DTI data to compare groups. The emerging tool
of magnetization transfer ratio (MTR) imaging may also be useful in assessing microstructural brain
changes related to clinical deficit [28].
These findings suggest that imaging markers correlate with aspects of disease severity, which
contributes to our understanding of the pathophysiology of NPC. However, we are unable to provide
enough support for prognostication of disease severity based on our study alone, because NPC’s rare
disease status limits the number of subjects required to show correlations between measurements, and
there is a significant amount of variance inherent in DTI measures.
Furthermore, our data show that in the inferior peduncle, miglustat has a paradoxical effect at high
FA values, as severity scores of patients on miglustat surpass those who are off of the drug. In almost
all other regions, as displayed in Figure 3 for swallowing subscore in the superior peduncle, we see
miglustat associated with lower severity scores across the spread of FA, MD or volume, except at the
very lowest MD levels, closest to where we would expect healthy control subjects to fall. The inferior
cerebellar peduncle is composed mostly of the restiform body, a collection of afferent fibers from the
posterior spinocerebellar tract of the spinal cord and various tracts from the medulla. The remaining
juxtarestiform body is primarily composed of efferent fibers from the vestibulocerebellum to the
vestigial nuclei, and from the fastigial nucleus to the uncinate fasciculus [29]. The “equilibrating effect”
of miglustat that our data show in the region of the inferior peduncle suggests that the mechanism of
action of miglustat may differ in the inferior peduncle compared to the rest of the cerebellum. This may
be due to the mixed afferent/efferent cellular make-up of the peduncle, but further research into the
mechanism of action of miglustat is warranted to explore this phenomenon further.
Finally, a previous publication investigating effects of volume and FA reduction and increased
MD in the corpus callosum on NNSS showed that ambulation, speech, swallow, motor, cognition,
memory, seizures and incontinence had a strong negative correlation with whole corpus callosum FA
and volume. Our findings in the cerebellum differ in that increased subscores were limited mostly to
motor function, with eye movement, ambulation, speech, and swallowing most significantly affected,
which would be expected with the known motor function of the cerebellum in the CNS. Similar to the
trends observed in the corpus callosum study, these increased NNSS were more often associated with
decreased FA and volume, as compared to increased MD. These correlations in the cerebellum are less
strong than those found in the corpus callosum study, suggesting that the corpus callosum is more
directly affected by the neuronal changes seen with NPC. Alternatively, a broader array of functional
impairment is anticipated with corpus callosum impairment, when compared to the cerebellum.
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Study Limitations
One limitation of this study is that our control group for z-score calculation did not have the same
scan parameters as our study population, thus direct comparison analysis was not possible. Likewise,
no longitudinal study of healthy control subjects was available to provide information about the effects
of age on rate of change in FA, volume and MD in the developing child’s brain. Studies have shown
that FA changes with age, but it is still unclear if changes vary in different regions at different stages
of child development. That being said, two statistical analyses (spearman correlation and multiple
regression analysis) were performed to account for age as a confounder. Findings from both analyses
support the conclusions of the study. Multiple regression analysis accounted for the covariate of age
at scan (or noise) in examining the associations between FA, volume, and MD of various cerebellar
regions and NNSS; essentially stronger statistical evidence of an association. Alternatively, ANCOVA
highlighted the independent effects of various FA, volume, and MD of cerebellar regions or miglustat
therapy, and an interaction effect between cerebellar FA, volume, and MD and miglustat therapy for
particular NPC subscores.
The NNSS does not capture all of the motor impairment in NPC patients, and is therefore
not a comprehensive evaluation of motor dysfunction. Likewise, the cerebellum does not account
for all of the body’s motor function. In our study, these inherently incomplete measures of motor
severity, juxtaposed with imaging parameters of one CNS region, limits generalization of findings.
Additionally, we relied on an automated parcellation to calculate volume, as a previous study validated
this automated method using manual tracing as the gold standard [8].
5. Conclusions
In a population of pediatric and adolescent NPC1 patients, impaired cerebellar volume and DTI
measures are associated with disease severity, particularly motor dysfunction. Furthermore, our data
suggest that the mechanism of action of miglustat may differ in the inferior peduncle compared with
the rest of the cerebellum. Longitudinal studies using DTI and neurodevelopmental data should be
performed to further advance our scientific understanding of NPC.
Supplementary Materials: The supplementary materials are available online at www.mdpi.com/2079-9721/4/
3/29/s1.
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Abbreviations
The following abbreviations are used in this manuscript:
NPC Niemann-Pick Disease, type C
NPC1 Niemann-Pick Disease, type C1
NPC2 Niemann-Pick Disease, type C2
DTI diffusion tensor imaging
FA fractional anisotropy
MD mean diffusivity
NNSS NIH NPC severity score
MRI magnetic resonance imaging
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MPRAGE spatially matched axial magnetization-prepared rapid-gradient echo
T2WI T2-weighted imaging
LDDMM Large deformation diffeomorphic metric mapping
ANCOVA Analysis of covariance
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